Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seviteronel in AR-Positive GBM
NCT03600467Phase 2Terminated
- Sponsor
- St Vincent's Hospital
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of seviteronel in glioblastoma (GBM), sponsored by St Vincent's Hospital. Started Aug 2018; status: terminated.
02
Drugs
seviteronel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03600467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600467.